Efficacy and Safety of Oral Kanglaite (KLTc) in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy.

Trial Profile

Efficacy and Safety of Oral Kanglaite (KLTc) in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2014

At a glance

  • Drugs Kanglaite (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors KangLaiTe USA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jan 2014 According to ClinicalTrials.gov record; study status changed from active, no longer recruiting to discontinued.
    • 06 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top